论文部分内容阅读
本文报道糖尿病并血脂异常患者140例,糖尿病血脂正常患者107例;血脂异常非糖尿病患者120例,均服用血脂康,结果治疗前后有明显差别(P<0.001),而组间相比无统计学差别(P>0.05),说明血脂康不影响降糖药的临床疗效。与既往所治疗的只服降糖药而不伍用调脂药的糖尿病并血脂异常病人降糖效果的对比分析认为,降糖调脂同时进行更有利于降糖(P<0.05)。糖尿病并血脂异常与单纯血脂异常2组,治疗前后血脂各指标组内相比均有明显差异(P<0.001),而两组间各相对应指标相比均无统计学差异(P>0.05)。说明血脂康对糖尿病人及非糖尿病人均有降脂或调脂作用。
This article reports 140 cases of diabetic patients with dyslipidemia, 107 cases of normal blood lipids in patients with diabetes; 120 cases of non-diabetic patients with dyslipidemia, were taking Xuezhikang results before and after treatment were significantly different (P <0.001), but no statistical difference between groups (P> 0.05), indicating that Xuezhikang does not affect the clinical efficacy of hypoglycemic agents. Contrastive analysis of the hypoglycemic effects of the previously treated patients with only hypoglycemic agents and no lipid-lowering agents in patients with dyslipidemia suggests that hypoglycemic and lipid lowering are more beneficial to hypoglycemic (P <0.05) at the same time. Diabetes mellitus and dyslipidemia were significantly different from those in the two groups (P <0.001), but no significant difference was found between the two groups (P> 0.05) . Description Xuezhikang Diabetes and non-diabetic people have lipid-lowering or lipid-lowering effect.